Bioceres Subsidiary Raises $20M in Bond Offering
Ticker: BIOX · Form: 6-K · Filed: Jul 1, 2024 · CIK: 1769484
Sentiment: bullish
Topics: debt-financing, subsidiary-offering, corporate-bonds
TL;DR
Bioceres subsidiary Rizobacter just closed a $20M bond offering. Bullish for growth.
AI Summary
Bioceres Crop Solutions Corp. announced on July 1, 2024, that its subsidiary, Rizobacter Argentina S.A., successfully completed an offering of Series IX Corporate Bonds, raising $20.0 million. This offering is part of Rizobacter's ongoing financing activities.
Why It Matters
This bond offering provides Bioceres' subsidiary with significant capital, potentially supporting its growth and operational expansion in the agricultural sector.
Risk Assessment
Risk Level: medium — While the bond offering provides capital, the success of the subsidiary and the broader agricultural market conditions present inherent risks.
Key Numbers
- $20.0M — Bond Offering Proceeds (Capital raised by Rizobacter Argentina S.A.)
Key Players & Entities
- Bioceres Crop Solutions Corp. (company) — Registrant
- Rizobacter Argentina S.A. (company) — Subsidiary completing bond offering
- $20.0 million (dollar_amount) — Amount raised in bond offering
- July 1, 2024 (date) — Date of announcement and bond offering completion
FAQ
What is the purpose of the $20.0 million Series IX Corporate Bonds offering?
The filing states that the offering is part of Rizobacter Argentina S.A.'s ongoing financing activities, implying it's for general corporate purposes and operational needs.
When was the Series IX Corporate Bonds offering completed?
The offering was completed on July 1, 2024.
Which subsidiary of Bioceres Crop Solutions Corp. completed the bond offering?
The subsidiary that completed the bond offering is Rizobacter Argentina S.A.
What is the total amount raised by Rizobacter Argentina S.A. in this bond offering?
Rizobacter Argentina S.A. raised $20.0 million in the Series IX Corporate Bonds offering.
What type of financial instrument was issued by Rizobacter Argentina S.A.?
Rizobacter Argentina S.A. issued Series IX Corporate Bonds.
Filing Stats: 790 words · 3 min read · ~3 pages · Grade level 14.3 · Accepted 2024-07-01 08:29:14
Key Financial Figures
- $20.0 Million — ary Rizobacter Argentina S.A. Completes $20.0 Million Offering of Series IX Corporate Bonds
- $20.0 million — uo;Rizobacter”) has completed a US$20.0 million public offering of Series IX corporate
- $13.0 million — wo tranches: Class A : Approximately US$13.0 million 5.0% p.a. bonds due June 2026; and Cla
- $7.0 million — ne 2026; and Class B : Approximately US$7.0 million 7.5% p.a. bonds due June 2026. Proceed
Filing Documents
- tm2418576d1_6k.htm (6-K) — 15KB
- tm2418576d1_6kimg001.jpg (GRAPHIC) — 5KB
- 0001104659-24-076587.txt ( ) — 23KB
Forward-looking statements
Forward-looking statements This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements are based on management’s reasonable current assumptions, expectations, plans and forecasts regarding the Company’s current or future results and future business and economic conditions more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels of activity, performance or achievement of the Company to be materially different from any future results expressed or implied by such forward-looking statements, and there can be no assurance that actual results will not differ materially from management’s expectations or could affect the Company’s ability to achieve its strategic goals, including the uncertainties relating to the impact of the armed conflict between Israel and Gaza, the Ukraine and Russia, and of COVID-19 on the Company’s business, operations, liquidity and financial results and the other factors that are described in the sections entitled “Risk Factors” in the Company's Securities and Exchange Commission filings updated from time to time. The preceding list is not intended to be an exhaustive list of all of our forward-looking
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BIOCERES CROP SOLUTIONS CORP. (Registrant) Dated: July 1, 2024 By: /s/ Federico Trucco Name: Federico Trucco Title: Chief Executive Officer